by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
by Lisa Willemse | Apr 25, 2014
> Julia Pon is a MD/PhD student at the University of British Columbia with an interest in blood cancer. Like many before her, she noticed that the kind of information that is shared with cancer patients is different than what medical students are taught about the...
by Paul Krzyzanowski | Apr 22, 2014
> If you’ve stayed current with the STAP cell fiasco you know it’s been a wild ride. STAP cells, or Stimulus-Triggered Acquisition of Pluripotency cells, caught the imagination of many in late January through their sheer simplicity: You hit cells with a shock of...
by Roshan Yoganathan | Apr 17, 2014
Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the...
by David Kent | Apr 15, 2014
> In February this year, the biggest stem cell trial for heart attack patients was begun and will involve over 3000 patients from 11 different countries in Europe. The BAMI trial (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on...
by Lisa Willemse | Apr 11, 2014
> I’ve been thinking a fair bit about the “personalities” of stem cells in recent weeks — specifically, the characteristics of stem cells that might translate into a persona or a fictional character of some sort. It’s with good reason,...
by Sara M. Nolte | Apr 8, 2014
> The thing that is so intriguing about cancer stem cells (CSCs), from a cancer researcher’s perspective, is their powerful potential as therapeutic targets. While CSCs can create or regenerate tumours (causing relapse in some patients despite our best efforts to...
by Stacey Johnson | Apr 4, 2014
. This intriguing title is not completely my own. It is a shorter version of Alysson Muotri’s (UCSD) title from a presentation he gave to the governing Board of the California Institute of Regenerative Medicine on March 13, 2014: “Reversing Autism in the Lab with...
by Alessandra Pasut | Apr 2, 2014
Editor’s note: Some of the links included are Italian language sources The case involving Stamina Foundation and the legitimacy of its stem cell treatments has been one of the most discussed and controversial issues in the international stem cell policy scene....
by Lisa Willemse | Mar 28, 2014
> Michael Rudnicki has been studying muscle biology for a long time… all the way back to his days as a graduate student. In this time, he’s contributed greatly to our understanding about muscle formation and the molecular “switches” that...
Comments